Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two years ...

Symptoms to look out for and when to see a doctor - There are roughly 10,000 people a year diagnosed with bladder cancer in the UK ...

Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the disease returning by a third ...

Researchers from the University of Sheffield and Barts Cancer Institute at Queen Mary, University of London have found that ...

A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to see the disease progress or return ...

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...